Bolt Biotherapeutics

Bolt Biotherapeutics ROCE

The Return on Capital Employed (ROCE) of Bolt Biotherapeutics (BOLT) as of Nov 5, 2026 is -130.67 %. In the previous year, Return on Capital Employed (ROCE) was -127.71 % — a change of 2.31% (lower).

ROCE

-130.67 %

YoY

2.31%

Last updated:

In 2025, Bolt Biotherapeutics's return on capital employed (ROCE) was -130.67 %, a 2.31% increase from the -127.71 % ROCE in the previous year.

The Bolt Biotherapeutics ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
72.94 USD
Jan 1, 2019
67.55 USD
Jan 1, 2020
46.86 USD
Jan 1, 2021
-37.10 USD
Jan 1, 2022
-52.66 USD
Jan 1, 2023
-67.58 USD
Jan 1, 2024
-127.71 USD
Jan 1, 2025
-130.67 USD
The Bolt Biotherapeutics ROCE history
YEARROCEYoY
-130.67 %+2.31%
-127.71 %+88.96%
-67.58 %+28.33%
-52.66 %+41.96%
-37.10 %-179.16%
46.86 %-30.62%
67.55 %-7.39%
72.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bolt Biotherapeutics Stock analysis

What does Bolt Biotherapeutics do? Bolt Biotherapeutics, Inc. develops immunotherapies for cancer treatment using its proprietary Boltbody ISAC platform, which combines tumor-targeting antibodies with immune-stimulating linker payloads. The company's first product, BDC-1001, targets HER2 and has completed dose-escalation trials, advancing into Phase II studies. BDC-3042, a Dectin-2 agonist antibody program, aims to repolarize tumor-associated macrophages in the tumor microenvironment. The company generates revenue through clinical development and potential future commercialization of its therapies, focusing on oncology indications. Bolt Biotherapeutics targets the biopharmaceutical sector with its novel immunotherapy platform, primarily engaging in research and development of cancer treatments. Its products are designed to work with the patient's immune system to create anti-cancer efficacy with tolerability. The company's clinical-stage development of BDC-1001 and BDC-3042 positions it for potential partnerships or licensing deals with pharmaceutical companies seeking innovative oncology solutions. The company's revenue model relies on the progression of its clinical programs toward regulatory approval and eventual market entry. BDC-1001 and BDC-3042 are being developed for specific cancer indications, with BDC-1001 targeting HER2-positive cancers and BDC-3042 focusing on tumor microenvironment modulation. Bolt Biotherapeutics may secure funding through partnerships, grants, or future product sales once clinical trials demonstrate efficacy and safety. Bolt Biotherapeutics is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Bolt Biotherapeutics's Return on Capital Employed (ROCE)

Bolt Biotherapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Bolt Biotherapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Bolt Biotherapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Bolt Biotherapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Bolt Biotherapeutics stock

Return on Capital Employed (ROCE) of Bolt Biotherapeutics is -130.67 % in 2025.

Return on Capital Employed (ROCE) of Bolt Biotherapeutics changed from -127.71 % to -130.67 %, representing a 2.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Bolt Biotherapeutics since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Bolt Biotherapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Bolt Biotherapeutics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Bolt Biotherapeutics